News

Ind-Swift Laboratories Ltd. will hold a board meeting on Thursday, October 29, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ind-Swift Laboratories Limited announced that its Preferential Issue Committee has approved the allotment of 14,00,000 equity shares with a face value of Rs 10 each to Essix Biosciences Limited, a promoter group entity, upon the conversion of an equal number of fully convertible warrants. The conversion involved a consideration of Rs 147 per warrant, totaling Rs 20,58,00,000, and was executed at an issue price of Rs 196 per warrant. Consequently, the company`s paid-up equity share capital increased from Rs 86,71,15,580 comprising 8,67,11,558 equity shares to Rs 86,96,15,580 comprising 8,69,61,558 equity shares.

Ind-Swift Laboratories Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange of India confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as received from Alankit Assignments Limited, the company`s Registrar and Share Transfer Agent.

Ind-Swift Laboratories Limited announced that its Preferential Issue Committee approved the allotment of 70,00,000 fully convertible warrants at a price of Rs 196 per warrant, including a premium of Rs 186, to Essix Biosciences Limited, an entity belonging to the ‘Promoter & Promoter Group,’ for a total subscription price of Rs 34,30,00,000.

IND-SWIFT LABORATORIES LTD. announced the appointment of Mr. Amit Mathur as an Additional Director, in the category of Non-Executive Independent Director, effective September 3, 2026, for a period of five years subject to member approval at the company’s 31st Annual General Meeting, scheduled for September 30, 2026. The company also announced the reconstitution of its Audit Committee, effective September 3, 2026, and appointed Care Ratings Limited as the Monitoring Agency for the utilization of proceeds from a preferential issue approved on August 5, 2026.